In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status. Impaired kidney function is the principal predictor of hemorrhage in ...

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

This means apixaban cut the clot risk by nearly half. It also improved the chances of keeping the vascular access working without further issues (32% failure rate versus 50% in the control group).

"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

Patients were randomly assigned to be treated with either 5 mg (2.5mg twice daily; the reduced-dose group) or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months.